Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

被引：0
作者：
S. E. de Boer
J. S.F. Sanders
F. J. Bemelman
M. G.H. Betjes
J. G.M. Burgerhof
L. Hilbrands
D. Kuypers
B. C. van Munster
S. A. Nurmohamed
A. P.J. de Vries
A. D. van Zuilen
D. A. Hesselink
S. P. Berger
机构：
[1] University of Groningen,Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen
[2] Amsterdam Universal Medical Center,Department of Internal Medicine, Division of Nephrology
[3] Erasmus University Medical Center,Department of Internal Medicine, Division of Nephrology & Transplantation, Erasmus MC
[4] University Medical Center Groningen,Department of Epidemiology
[5] University of Groningen,Department of Internal Medicine, Division of Nephrology
[6] Radboud University Medical Center,Department of Nephrology and Renal Transplantation
[7] University Hospitals Leuven,Department of Internal Medicine, Divison of Geriatrics, University Medical Center Groningen
[8] University of Groningen,Department of Internal Medicine, Division of Nephrology; and Leiden Transplant Center
[9] Leiden University Medical Center,Department of Internal Medicine, Division of Nephrology
[10] Leiden University,undefined
[11] University Medical Center Utrecht,undefined
来源：
BMC Nephrology | / 22卷
关键词：
Elderly kidney transplant recipients; Reduced CNI exposure; mTOR inhibitor; Everolimus; (Health-related) quality of life; Patient-reported outcomes; Frailty; Immunosenescence; Randomized clinical trial; Multicenter trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 90 条
[11]  
Silvestre C(2008)Prospective Age-Matching in Elderly Kidney Transplant Recipients—A 5-Year Analysis of the Eurotransplant Senior Program Am J Transplant 1 50-84
[12]  
Donato P(2009)Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 481-69
[13]  
Tullius SG(2017)Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients Cochrane Database of Systematic Reviews 7 CD006750-602
[14]  
Tran H(2014)Belatacept for kidney transplant recipients Cochrane Database of Systematic Reviews 11 CD010699-34
[15]  
Guleria I(2016)Clinical consequences of circulating CD28-negative T cells for solid organ transplantation Transpl Int 29 274-91
[16]  
Malek SK(2012)Three-year outcomes in elderly kidney transplant recipients treated with belatacept vs cyclosporine in BENEFIT-EXT Am J Transplant 12 403-30
[17]  
Tilney NL(2017)Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data Am J Transplant 17 1358-undefined
[18]  
Milford E(2012)Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation Transpl Int 25 592-undefined
[19]  
Betjes MGH(2019)Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study Am J Transplant 19 3018-undefined
[20]  
Langerak AW(2018)Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation J Am Soc Nephrol 29 1979-undefined
123456789